Economic Burden of Immune Thrombocytopenia (ITP) In Patients Receiving Eltrombopag (EPAG) And Romiplostim (ROMI)- Real World Evidence From 26 US Institutions
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.870
https://www.valueinhealthjournal.com/article/S1098-3015(17)31204-4/fulltext
Title :
Economic Burden of Immune Thrombocytopenia (ITP) In Patients Receiving Eltrombopag (EPAG) And Romiplostim (ROMI)- Real World Evidence From 26 US Institutions
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31204-4&doi=10.1016/j.jval.2017.08.870
First page :
A552
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
833